T cell receptors (TCRs) are protein complexes formed by six different polypeptides. The CD3 (cluster of differentiation 3) complex is part of the T-cell receptor (TCR) complex and is composed of two CD3ε, one CD3γ, one CD3δ, and two CD3ζ chains.1,2 CD3 complex ensures signal transduction and plays an important role in T-cell activation.1-3A bispecific antibody approach may allow for binding to targets on malignant cells, while simultaneously binding to CD3 on T cells, inducing activation and cytotoxic activity of T cells enabling lysis of target-expressing malignant cells.1,5
Diagram of the T-cell receptor (TCR) complex.
CD3 bispecific antibodies (bsAb) induce the activation and cytotoxic activity of effector T cells enabling lysis of target-expressing malignant cells.1,3,5
T-cell redirection with bispecific antibodies in which one binding arm recognizes a tumor antigen and the other binding arm recognizes CD3 on T-cells.
CD3 bsAbs in clinical trials either lack an Fc region or contain an engineered Fc domain to minimize interaction with Fc receptors.1,3
A key CD3 bsAb development consideration is a need for a format that either significantly limits or eliminates cyokine release syndrome (CRS), since CRS appears to be dose-limiting in most cases for this class of molecules1
Immunotherapy of cancer with CD3 bsAb is a fast developing field, and multiple TAAs are under evaluation for both hematological and solid tumor malignancies with > 44 different CD3 bs Abs in clinical development.3,5
CD20 (cluster of differentiation 20) on B-cells is a clinically well-validated target that is expressed in a wide variety of B-cell malignancies with limited normal tissue expression beyond B cells.7,8
Survivin, an essential apoptotic-related protein, is an attractive intracellular tumor target expressed in multiple solid and hematological cancers that is readily amenable to TCR-directed therapeutics.4
5T4 (trophoblast glycoprotein, TPBG) is an oncofetal antigen and overexpression of the 5T4 gene in different cell types is characterized by morphological changes, inhibition of cell-cell interaction, E-cadherin downregulation, cytoskeletal disruption, reduced adherence, and increased motility.9
5T4 is a transmembrane tumor antigen expressed in multiple tumor types with limited expression in healthy tissue.10
The site you have requested is intended to provide information for healthcare professionals residing in the US or Puerto Rico.
I am a licensed healthcare professional residing in the US or Puerto Rico.
I am not a licensed healthcare professional residing in the US or Puerto Rico.
Contact Medical Information
For All Other Information